What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Immune system
His primary areas of study are Immunology, T cell, Cytotoxic T cell, CD8 and IL-2 receptor.
Immunotherapy, Adoptive cell transfer and Immune system are the core of his Immunology study.
His Immunotherapy study incorporates themes from Improved survival and Histology.
As part of his studies on T cell, Christopher A. Klebanoff often connects relevant subjects like Cancer research.
Particularly relevant to Interleukin 21 is his body of work in Cytotoxic T cell.
His studies deal with areas such as Interleukin 2 and Cell biology as well as CD8.
His most cited work include:
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types. (848 citations)
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types. (848 citations)
- Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells (810 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Immunology, CD8, T cell, Cancer research and Immunotherapy.
In his work, Cellular differentiation is strongly intertwined with Cytotoxic T cell, which is a subfield of Immunology.
His CD8 research also works with subjects such as
- Cell biology which intersects with area such as Cell growth,
- Effector which connect with Transcription factor.
His work investigates the relationship between T cell and topics such as FOXP3 that intersect with problems in Acquired immune system.
His Cancer research research is multidisciplinary, relying on both Cell, Cytokine, Tumor microenvironment, Apoptosis and T-cell receptor.
His biological study deals with issues like Oncology, which deal with fields such as Multiple cancer, Histology and Immune checkpoint inhibitors.
He most often published in these fields:
- Immunology (53.39%)
- CD8 (43.22%)
- T cell (42.37%)
What were the highlights of his more recent work (between 2018-2021)?
- T-cell receptor (32.20%)
- Cancer research (39.83%)
- Cancer immunotherapy (20.34%)
In recent papers he was focusing on the following fields of study:
His main research concerns T-cell receptor, Cancer research, Cancer immunotherapy, Antigen and Receptor.
His T-cell receptor research integrates issues from Epitope, Cancer, In vitro and Computational biology.
His research in Cancer research intersects with topics in Tumor microenvironment, Phase i study, Chimeric antigen receptor and Head and neck.
His research investigates the connection with Tumor microenvironment and areas like Genetic enhancement which intersect with concerns in Immunotherapy.
The concepts of his Cancer immunotherapy study are interwoven with issues in T cell and Adoptive cell transfer.
His research integrates issues of Cytotoxic T cell and Effector in his study of T cell.
Between 2018 and 2021, his most popular works were:
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types. (848 citations)
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types. (848 citations)
- TOX is a critical regulator of tumour-specific T cell differentiation (231 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Immune system
Christopher A. Klebanoff mainly focuses on T cell, Cancer research, Cancer immunotherapy, T-cell receptor and Effector.
Christopher A. Klebanoff combines subjects such as Cytotoxic T cell and Antigen with his study of T cell.
His work carried out in the field of T-cell receptor brings together such families of science as Apoptosis, Adoptive cell transfer, Chimeric antigen receptor and Fas ligand.
Christopher A. Klebanoff interconnects Autophagy, Tumor microenvironment, CD8, Immune tolerance and Histone in the investigation of issues within Effector.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
